158 related articles for article (PubMed ID: 21811139)
1. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants.
Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
AIDS; 2011 Oct; 25(16):1971-9. PubMed ID: 21811139
[TBL] [Abstract][Full Text] [Related]
2. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
Herrera C; Armanasco N; García-Pérez J; Ziprin P; Olejniczak N; Alcamí J; Nuttall J; Shattock RJ
AIDS; 2016 Apr; 30(7):1015-25. PubMed ID: 26854808
[TBL] [Abstract][Full Text] [Related]
3. Reverse transcriptase inhibitors as potential colorectal microbicides.
Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
Antimicrob Agents Chemother; 2009 May; 53(5):1797-807. PubMed ID: 19258271
[TBL] [Abstract][Full Text] [Related]
4. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
Schader SM; Colby-Germinario SP; Schachter JR; Xu H; Wainberg MA
AIDS; 2011 Aug; 25(13):1585-94. PubMed ID: 21633286
[TBL] [Abstract][Full Text] [Related]
5. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection.
Abner SR; Guenthner PC; Guarner J; Hancock KA; Cummins JE; Fink A; Gilmore GT; Staley C; Ward A; Ali O; Binderow S; Cohen S; Grohskopf LA; Paxton L; Hart CE; Dezzutti CS
J Infect Dis; 2005 Nov; 192(9):1545-56. PubMed ID: 16206069
[TBL] [Abstract][Full Text] [Related]
6. Microbicides for multidrug-resistant and multitropic HIV-1.
D'Cruz OJ; Uckun FM
Curr Opin Investig Drugs; 2008 Feb; 9(2):152-69. PubMed ID: 18246518
[TBL] [Abstract][Full Text] [Related]
7. Carrageenan/MIV-150 (PC-815), a combination microbicide.
Fernández-Romero JA; Thorn M; Turville SG; Titchen K; Sudol K; Li J; Miller T; Robbiani M; Maguire RA; Buckheit RW; Hartman TL; Phillips DM
Sex Transm Dis; 2007 Jan; 34(1):9-14. PubMed ID: 16924181
[TBL] [Abstract][Full Text] [Related]
8. Resistance against reverse transcriptase inhibitors.
O'Brien WA
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.
Fletcher PS; Elliott J; Grivel JC; Margolis L; Anton P; McGowan I; Shattock RJ
AIDS; 2006 Jun; 20(9):1237-45. PubMed ID: 16816551
[TBL] [Abstract][Full Text] [Related]
10. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
[TBL] [Abstract][Full Text] [Related]
12. The future of HIV prevention: prospects for an effective anti-HIV microbicide.
Nuttall J; Romano J; Douville K; Galbreath C; Nel A; Heyward W; Mitchnick M; Walker S; Rosenberg Z
Infect Dis Clin North Am; 2007 Mar; 21(1):219-39, x. PubMed ID: 17502237
[TBL] [Abstract][Full Text] [Related]
13. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
[TBL] [Abstract][Full Text] [Related]
14. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.
Njai HF; Lewi PJ; Janssen CG; Garcia S; Fransen K; Kestens L; Vanham G; Janssen PA
Antivir Ther; 2005; 10(2):255-62. PubMed ID: 15865220
[TBL] [Abstract][Full Text] [Related]
15. Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission.
Zhang W; Hu M; Shi Y; Gong T; Dezzutti CS; Moncla B; Sarafianos SG; Parniak MA; Rohan LC
Pharm Res; 2015 Sep; 32(9):2960-72. PubMed ID: 25794967
[TBL] [Abstract][Full Text] [Related]
16. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
Richardson-Harman N; Mauck C; McGowan I; Anton P
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1422-33. PubMed ID: 22900504
[TBL] [Abstract][Full Text] [Related]
17. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
Ketas TJ; Schader SM; Zurita J; Teo E; Polonis V; Lu M; Klasse PJ; Moore JP
Virology; 2007 Aug; 364(2):431-40. PubMed ID: 17428517
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
[TBL] [Abstract][Full Text] [Related]
19. Sustained release of microbicides by newly engineered vaginal rings.
Saxena BB; Han YA; Fu D; Rathnam P; Singh M; Laurence J; Lerner S
AIDS; 2009 May; 23(8):917-22. PubMed ID: 19381077
[TBL] [Abstract][Full Text] [Related]
20. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
